Amarin makes its entry into cardiovascular research and development and opens its R&D headquarters in Mystic, Connecticut.

Receives Special Protocol Assessment for its Phase 3 MARINE study evaluating AMR-101’s ability to lower triglycerides.

Commences first patient in REDUCE-IT, The Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial.”

Receives first FDA approval of VASCEPA® for its initial indication.

Amarin and Eddingpharm announce an agreement to develop and commercialize in China.

Amarin BOLDLY affirms its right to promote under the First Amendment Litigation Settlement Terms and enrolls the final patients into the REDUCE-IT™ study.

Amarin and HLS Therapeutics announce an agreement to commercialize in Canada.

Reports positive results from the study and files for FDA approval.

Amarin receives FDA approval for its second indication.

Enters into the European market with approval from the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency. 

Amarin announces an exclusive long-term agreement with Lotus Pharmaceuticals to distribute and commercialize VAZKEPA® across ten countries in Southeast Asia and South Korea. An exclusive marketing and commercial agreement is announced with Neopharm for VAZKEPA® in Israel, and reimbursement is secured in Spain, Scotland, and the Netherlands.

Reimbursement is secured in Portugal, Italy, and Greece, with a partnership with Vianex. EddingPharm receives regulatory approval for VASCEPA® in Mainland China for the CVRR indication.